HEALWELL AI Provides Corporate Update on Capital Allocation Program and Value Creation Strategy
HEALWELL AI Provides Corporate Update on Capital Allocation Program and Value Creation Strategy
- HEALWELL's current goal is to achieve run rate revenues approaching $100 million by the end of the year from today's current run rate of over $65 million. This goal is underpinned by a robust M&A pipeline where there are several advanced subjects including one signed LOI and helps the Company position itself to achieve profitability on an Adjusted EBITDA basis in 2025.
- HEALWELL's four acquisitions to date have positioned the company to unlock the power of health data with artificial intelligence for three key stakeholder groups: (i) Clinicians in healthcare clinics with co-pilot offerings; (ii) Large enterprises such as Canadian Provincial Healthcare systems with Data Interoperability, population health and related services; and (iii) The pharmaceutical industry with a multi-tiered offering that includes scientific research, real-world evidence and clinical trials orchestration services.
- HEALWELL is focused on continuing to grow and build on each of these segments both organically and inorganically using its capital allocation program.
- The Company reiterates its disclosure from July 10th, 2024 that HEALWELL had recently strengthened its balance sheet by removing $15.5 million in total liabilities and had cash in excess of $14.5 million at the end of the second quarter. The Company also disclosed that if all of the Company's in-the-money warrants were to be exercised, HEALWELL's cash balance is expected to grow to an amount in excess of $39 million.
- HEALWELL目前的目標是實現按年計算的營業收入,從今天的超過6500萬美元的運營水平到年底接近1億美元。這一目標得到了強有力的併購管道的支撐,其中包括幾個先進的主題,包括已簽署的LOI,並幫助公司在2025年實現基於調整後EBITDA的盈利能力。
- HEALWELL迄今爲止的四個收購使該公司能夠爲三個關鍵利益相關者解鎖健康數據與人工智能的力量:(i)醫療診所中的臨床醫生提供聯合駕駛員服務;(ii)加拿大省級醫療保健系統等大型企業提供數據互操作性、人口健康和相關服務;以及(iii)製藥行業提供包括科學研究、真實世界證據和臨床試驗編排服務在內的多層次服務。
- HEALWELL專注於繼續通過其資本配置計劃在這些領域中實現有機和非有機的增長和建設。
- 公司重申了2024年7月10日的披露,即HEALWELL最近通過清理總負債15.5百萬美元和第二季度末現金超過14.5百萬美元的方式加強了其資產負債表。該公司還披露,如果公司所有實際轉換的權證都被行使,預計HEALWELL的現金餘額將增長到超過3900萬美元。
Toronto, Ontario--(Newsfile Corp. - July 23, 2024) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare technology company focused on AI and data science for preventative care, is pleased to provide a corporate update highlighting recent advancement in the Company's acquisition strategy. HEALWELL's current goal is to achieve run rate revenues approaching $100 million by the end of the year, up from today's current run rate of over $65 million. This ambitious target is supported by a robust M&A pipeline, which includes several advanced prospects and one signed LOI and supports the Company's goal of achieving profitability in 2025 on an Adjusted EBITDA basis.
加拿大安大略省--(Newsfile corp. - 2024年7月23日)-HEALWELL人工智能股份有限公司(TSX:AIDX)(OTCQX:HWAIF)("HEALWELL"或"公司"),是一家專注於預防護理人工智能和數據科學的醫療保健技術公司,高興地提供公司最近在收購策略方面取得的最新進展。 HEALWELL目前的目標是實現按年計算的營業收入,從今天的超過6500萬美元的運營水平到年底接近1億美元。這一雄心勃勃的目標得到了強有力的財務併購管道的支持,這些管道包括多個先進的前景和一個已經簽署的LOI,並支持公司在2025年的調整後EBITDA盈利目標。
Dr. Alexander Dobranowski, CEO of HEALWELL commented, "Our confidence in continuing to execute on our M&A pipeline grows every day as HEALWELL is becoming recognized as a high-quality acquirer in the digital health and life sciences marketplace. What is unique about our revenue growth strategy is not only our ability to acquire high quality growth assets but also our ability to integrate these assets with our industry leading artificial intelligence offerings in order to expand margins and accelerate growth."
HEALWELL的首席執行官Alexander Dobranowski博士評論道:“隨着HEALWELL在數字醫療和生命科學市場被認爲是高質量的收購者,我們繼續執行併購管道的信心日益增強。我們收入增長策略的獨特之處不僅在於我們收購高質量的增長資產的能力,還在於我們將這些資產與我們行業領先的人工智能產品相結合,以擴展利潤率並加速增長。”
Anthony Lam, CFO of HEALWELL commented, "HEALWELL is well positioned to continue its capital allocation program which is very focused on approaching the $100M run-rate figure by the end of the year. This growth also positions the Company to execute on its plans to achieve profitability in fiscal 2025 on an Adjusted EBITDA basis which we also believe is an important component of our value creation strategy and to deliver shareholder value."
HEALWELL首席財務官Anthony Lam評論道:“HEALWELL處於良好的位置,可以通過其資本配置計劃實現按年計算的營業收入接近1億美元的目標。這種增長也使公司能夠執行其計劃,在2025年的調整後EBITDA基礎上實現盈利,我們還認爲這是增長價值策略的一個重要組成部分,並提供股東價值。”
HEALWELL's four acquisitions to date, namely Pentavere Research Group Inc. ("Pentavere"), Intrahealth Systems Limited, VeroSource Services Inc. ("VeroSource") and BioPharma Services Inc. ("BioPharma"), have positioned the Company to unlock the power of health data with artificial intelligence for three key stakeholder groups:
HEALWELL迄今爲止的四個收購(即Pentavere研究集團公司("Pentavere"),Intrahealth Systems Limited,VeroSource Services Inc。 ("VeroSource")和BioPharma Services Inc。(“BioPharma”))已經爲三個關鍵利益相關者解鎖了健康數據和人工智能的力量:
- Clinicians in healthcare clinics with co-pilot offerings. To-date HEALWELL has launched AI enabled clinical co-pilot tools to support providers with Clinical Decision Support in four main domains: rare diseases, chronic diseases, cardiovascular disease and oncology. HEALWELL's strategy is to continue to develop AI enabled co-pilot tools to launch in parallel to the current offerings that are in-production and at scale.
- Large enterprises such as Canadian provincial healthcare systems with data interoperability and related services. Since the acquisition of VeroSource, HEALWELL now offers end-to-end, customizable, cloud-based data interoperability and population health capabilities. These capabilities enable public sector stakeholders to seamlessly access and interact with healthcare data. HEALWELL intends to expand on these offerings to public sector clients across multiple jurisdictions in Canada as it integrates its industry leading AI capabilities into its public sector offerings.
- The pharmaceutical industry with a multi-tiered offering that includes scientific research, real-world evidence and clinical trials orchestration services. With the acquisitions of Pentavere and BioPharama coupled with the capabilities of Khure Health, HEALWELL now has exceptional AI and clinical trial capabilities. These acquisitions have significantly increased the Company's ability to provide both clinical and commercial value for life sciences companies. The addition of BioPharma has expanded HEALWELL's clinical trial offerings to include bioequivalence and early-stage trial services, leveraging HEALWELL's AI capabilities to help identify patients of strong clinical trial eligibility.
- 醫療診所中的臨床醫生通過聯合飛行員服務迄今爲止,HEALWELL已經推出了AI啓用的臨床聯合飛行員工具,以支持提供者在四個主要領域中進行臨床決策支持:罕見病、慢性病、心血管疾病和腫瘤學。HEALWELL的策略是繼續開發AI啓用的聯合飛行員工具,並與當前正在生產和擴展規模的product並行推出。
- 加拿大省級醫療保健系統具有數據互操作性和相關服務。自收購VeroSource以來,HEALWELL現在提供端到端、可定製的基於雲的數據互操作性和人口健康能力。這些能力使公共部門利益相關者能夠無縫地訪問和交互醫療保健數據。HEALWELL計劃通過將其行業領先的人工智能能力整合到其公共部門提供的產品中,將這些產品擴展到加拿大多個司法轄區的公共部門客戶。
- 製藥行業,其中包括科學研究、真實世界證據和臨床試驗編排服務通過Pentavere和BioPharama的收購以及Khure Health的能力,HEALWELL現在擁有非常出色的人工智能和臨床試驗能力。這些收購使公司顯著提高了爲生命科學公司提供臨床和商業價值的能力。BioPharma的加入擴大了HEALWELL的臨床試驗服務範圍,包括生物等效性和早期試驗服務,利用HEALWELL的人工智能能力幫助識別具有強大臨床試驗資格的患者。
HEALWELL is focused on continuing its growth trajectory by building on each of these segments both organically and inorganically. The Company's capital allocation program will focus on two areas: first, early disease detection AI capabilities; and second, mature operating healthcare software, digital health and research companies that can be enhanced with HELAWELL's tools.
HEALWELL專注於繼續通過其資本配置計劃在這些領域中實現有機和非有機的增長和建設。公司的資本分配計劃將關注兩個領域:首先是早期疾病檢測AI能力;其次是成熟的運營醫療軟件、數字醫療和研究公司,這些公司可以通過HEALWELL的工具進行增強。
HEALWELL is also pleased to re-iterate its disclosure on July 10th, 2024 that the Company had recently strengthened its balance sheet by reducing total liabilities by $15.5M and had cash in excess of $14.5 million at the end of the second quarter. HEALWELL also disclosed that if all of the Company's in-the-money warrants were to be exercised, cash balance is expected to grow to an amount in excess of $39 million. The Company is well positioned to continue its successful capital allocation program and to deliver shareholder value.
HEALWELL也高興地再次重申其於2024年7月10日披露的內容,即該公司最近通過減少總負債1,550萬美元並在第二季度末持有超過1,450萬美元的現金來加強其資產負債表。HEALWELL還披露,如果公司所有實際轉換的權證都被行使,現金餘額預計將增長到超過3900萬美元。該公司有能力繼續其成功的資本配置計劃並提供股東價值。
Non-GAAP financial measures
非GAAP財務指標
The Company uses certain non-GAAP financial measures as supplemental indicators of its financial and operating performance. These non-GAAP financial measures include Adjusted EBITDA. The Company believes this supplementary financial measure reflects the Company's ongoing business in a manner that allows for meaningful analysis of trends in its business.
該公司使用某些非GAAP財務指標作爲其財務和營運表現的補充指標。這些非GAAP財務指標包括調整後EBITDA。公司認爲,這種補充財務指標以反映公司的經營方式,有助於對其業務趨勢進行有意義的分析。
Dr. Alexander Dobranowski
Chief Executive Officer
HEALWELL AI Inc.
首席執行官
首席執行官
關於HEALWELL AI
About HEALWELL AI
HEALWELL是一家專注於AI和數據科學的醫療技術公司,專注於預防保健。其使命是通過疾病的早期識別和發現來改善醫療保健並拯救生命。利用其獨有的專有技術,該公司正在開發和商業化先進的臨床決策支持系統,可以幫助醫療保健提供者檢測罕見和慢性疾病,提高他們的實踐效率,最終幫助提高患者的健康結果。HEALWELL正在執行以技術和臨床科學能力的發展和收購爲中心的戰略,這些能力與公司的路線圖相互補充。HEALWELL在多倫多證券交易所 (TSX) 上公開交易,股票代碼爲“AIDX”,在OTC Exchange上下市,股票代碼爲“HWAIF”。如果想了解更多HEALWELL的信息,請訪問
HEALWELL is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary AI technology and competencies which includes data science, electronic health records and clinical research offerings, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". To learn more about HEALWELL, please visit .
HEALWELL是一家專注於預防保健的醫療技術公司,專注於AI和數據科學。其使命是通過早期疾病識別和檢測改善醫療保健,並挽救生命。該公司正在開發和商業化先進的臨床決策支持系統,這些系統可以幫助醫療保健提供者檢測罕見和慢性疾病,提高其實踐的效率,最終幫助改善患者的健康結果。HEALWELL在多倫多證券交易所上市(股票代碼“AIDX”),在OTC Exchange上也上市(股票代碼“HWAIF”)。要了解有關HEALWELL的更多信息,請訪問其網站。
Forward-Looking Statements
前瞻性聲明
Certain statements in this press release, constitute "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities laws and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-Looking statements in this press release include statements with respect to, among other things, the Company's current and expected run rate revenue, its current M&A pipeline and other future acquisitions by the Company, its expected product offering and customer base, its ability to integrate artificial intelligence technologies into its product offering, and the potential exercise of the Company's outstanding warrants. Forward-Looking statements are often, but not always, identified by words or phrases such as "position", "growth", "future", "opportunity", "potential", "improve", "expect", "intend", "create" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms . Forward-Looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward-Looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: the Company's ability to successfully integrate recent acquisitions into its organization; the availability of future M&A opportunities and the Company's ability to capitalize on those opportunities; the anticipated timing and quantity of, and demand for, warrant exercises; the effects of competition in the industry; the expected demand for the Company's products and continued profitability of the target companies within its M&A pipeline; trends in customer growth; the stability of general economic and market conditions; currency exchange rates and interest rates; the Company's ability to comply with applicable laws and regulations; the Company's continued compliance with third party intellectual property rights; and that the risk factors noted below, collectively, do not have a material impact on the Company's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.
本新聞稿中的某些陳述構成"前瞻性信息"和"前瞻性聲明",依據適用的加拿大證券法,並基於在本新聞稿發佈之日的假設、期望、估計和預測。 本新聞稿中的前瞻性聲明包括關於公司當前和預期的營運收入、公司當前的M&A流水線和公司未來其他收購、公司預期的產品和客戶群、將人工智能技術整合到其產品中的能力以及潛在行權公司未行權認股權證的聲明。前瞻性聲明通常由“position”、“growth”、“future”、“opportunity”、“potential”、“improve”、“expect”、“intend”、“create”或這類單詞或短語形成,或聲明某些未來條件、行動、事件或結果“將“、“可能”、“可能”、“應該”、“可能”或“可以”被採取、發生或實現,或者這些術語中任何一個的否定。前瞻性聲明必然基於管理層對歷史趨勢、當前狀況和預期未來發展的看法,以及一些特定因素和假設,而這些特定因素和假設,雖然在本聲明被認爲是合理的,但在HEALWELL公司控制之外,並且天生面臨着重大的商業、經濟和競爭上的不確定性和意外情況,這可能最終使前瞻性聲明完全或部分不正確或不真實。本新聞稿中的前瞻性聲明基於各種假設,包括但不限於以下假設:公司能夠成功地將最近收購融入其組織中;未來的M&A機會可得到並且公司能夠利用這些機會;期權行權的預期時間、數量和需求;行業競爭的影響;公司產品的預期需求和其M&A流水線中目標公司的持續盈利能力;客戶增長趨勢;一般經濟和市場狀況的穩定性;貨幣匯率和利率;公司能夠遵守適用法律和法規;公司持續遵守第三方知識產權的權利;以下風險因素作爲整體對公司的業務、營運、收入和/或業績沒有重要影響。由於其特性,前瞻性聲明面臨潛在的一般或特定的固有風險和不確定性,這些風險和不確定性可能導致期望、預測、預測、預測或結論證明不準確,假設可能不正確,並且目標、戰略目標和優先事項將無法實現。
Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated April 1, 2024, which is available under HEALWELL's SEDAR+ profile at . The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-Looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.
許多已知和未知的風險因素,許多因素超出了HEALWELL的控制,這些因素可能會導致HEALWELL的實際結果與所述前瞻性陳述所表達或暗示的結果、表現、成就或發展存在實質性差異。這些風險因素包括但不限於在HEALWELL最近的2024年4月1日的最新年度信息表格中討論的那些因素,該表格可在HEALWELL的SEDA+個人資料中獲得。風險因素並非旨在代表可能影響HEALWELL的所有因素的完整列表,請讀者謹慎考慮這些和其他因素、不確定性和潛在事件,不要過度依賴前瞻性陳述。無法保證前瞻性陳述將被證明準確,因爲實際結果和未來事件可能與這些陳述中預期的有實質性不同。前瞻性陳述是爲了提供有關管理層未來的期望和計劃的信息而提供的。HEALWELL放棄任何更新或修訂任何前瞻性陳述的意向或義務,無論是基於新信息、未來事件或其他原因,或者解釋隨後實際事件和這些前瞻性陳述之間的任何實質性差異,除非適用法律要求。本新聞稿中包含的所有前瞻性陳述均受這些警示性陳述的限制。
For more information:
欲了解更多信息:
Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
ir@healwell.ai
Pardeep S. Sangha
投資者關係,HEALWELL AI Inc。
電話:604-572-6392
ir@healwell.ai